Anish Thomas Mbbs

List of Publications by Year in Descending Order

118 papers	4,302 citations	36 h-index	63 g-index
134 ext. papers	5,523 ext. citations	7.3 avg, IF	5.74 L-index

#	Paper	IF	Citations
118	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.. *Nature Communications*, **2022**, 13, 2023	17.4	1
117	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. *Cancer Cell*, **2021**, 39, 566-579.e7	24.3	24
116	Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. *Nature Communications*, **2021**, 12, 3880	17.4	11
115	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. *Science Translational Medicine*, **2021**, 13,	17.5	6
114	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. *Cancers*, **2021**, 13,	6.6	1
113	Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. *Journal of Thoracic Oncology*, **2021**,	8.9	3
112	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in Gene. *JTO Clinical and Research Reports*, **2021**, 2, 100231	1.4	1
111	Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation. *Clinical Cancer Research*, **2020**, 26, 2452-2456	12.9	6
110	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study. *Chest*, **2020**, 158, 1723-1733	5.3	6
109	Lenvatinib for thymic carcinomas. *Lancet Oncology, The*, **2020**, 21, 745-746	21.7	
108	Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases. *Journal of Thoracic Oncology*, **2020**, 15, e25-e27	8.9	
107	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. *Journal of Clinical Oncology*, **2020**, 38, 1824-1835	2.2	52
106	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. *Science Translational Medicine*, **2020**, 12,	17.5	11
105	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. *JAMA Network Open*, **2020**, 3, e200032	10.4	11
104	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. *Journal of Thoracic Oncology*, **2020**, 15, 843-859	8.9	26
103	F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis-The Central Role of Volume. *Journal of Nuclear Medicine*, **2020**, 61, 1570-1575	8.9	1
102	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. *Cell Reports*, **2020**, 33, 108296	10.6	32

101	Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumors. *Journal of Physical Education and Sports Management*, **2020**, 6,	2.8	1
100	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. *Cancer*, **2020**, 126, 4936-4947	6.4	11
99	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2020**, 86, 475-486	3.5	3
98	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2020**, 26, 828-836	12.9	18
97	Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?. *Lung Cancer Management*, **2019**, 8, LMT13	2.6	14
96	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. *JNCI Cancer Spectrum*, **2019**, 3, pkz010	4.6	3
95	Targeting Topoisomerase I in the Era of Precision Medicine. *Clinical Cancer Research*, **2019**, 25, 6581-6589	12.9	89
94	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. *Pharmacology & Therapeutics*, **2019**, 201, 94-102	13.9	63
93	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 9008-9013	11.5	67
92	Clinical Response of Live-Attenuated, Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. *Clinical Cancer Research*, **2019**, 25, 5787-5798	12.9	33
91	Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. *Journal of Thoracic Oncology*, **2019**, 14, 1447-1457	8.9	67
90	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. *Frontiers in Oncology*, **2019**, 9, 994	5.3	12
89	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma **2019**, 7, 269		43
88	Reply to Yan et al. *Journal of Thoracic Oncology*, **2019**, 14, e245-e246	8.9	
87	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. *JAMA Oncology*, **2019**, 5, 351-357	13.4	84
86	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (Expression with Class I Histone Deacetylase Inhibitors. *Clinical Cancer Research*, **2018**, 24, 1944-1953	12.9	42
85	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. *Clinical Cancer Research*, **2018**, 24, 2859-2872	12.9	25
84	Humoral and Cellular Immune Dysregulation and Lung Cancer **2018**, 137-142.e3		0

83	Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. *JCO Precision Oncology*, **2018**, 2018,	3.6	3
82	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. *Journal of Clinical Oncology*, **2018**, 36, 1594-1602	2.2	69
81	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2018**, 36, 1343-1373	2.2	215
80	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. *IScience*, **2018**, 10, 247-264	6.1	78
79	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. *journal of applied laboratory medicine, The*, **2018**, 3, 166-177	2	4
78	Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. *Chest*, **2018**, 154, 1284-1290	5.3	28
77	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. *Journal of Thoracic Oncology*, **2018**, 13, 1269-1283	8.9	54
76	Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010. *Lung Cancer*, **2017**, 103, 66-74	5.9	13
75	DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?. *Trends in Cancer*, **2017**, 3, 2-6	12.5	14
74	Temozolomide in the Era of Precision Medicine. *Cancer Research*, **2017**, 77, 823-826	10.1	61
73	DNA Topoisomerase Targeting Drugs **2017**, 1-17		2
72	Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. *Clinical Genitourinary Cancer*, **2017**, 15, e871-e875	3.3	2
71	Immunotherapeutic Approaches to Mesothelioma. *Current Cancer Research*, **2017**, 347-357	0.2	
70	Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. *Translational Lung Cancer Research*, **2017**, 6, 588-599	4.4	5
69	Malignant Mesothelioma Effusions Are Infiltrated by CD3 T Cells Highly Expressing PD-L1 and the PD-L1 Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *Journal of Thoracic Oncology*, **2016**, 11, 1993-2005	8.9	77
68	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. *Science Translational Medicine*, **2016**, 8, 346fs12	17.5	24
67	Mutations in Latinos From the United States and Latin America. *Journal of Global Oncology*, **2016**, 2, 259-267	2.7	8
66	Antibody-drug conjugates for cancer therapy. *Lancet Oncology, The*, **2016**, 17, e254-e262	21.7	282

65	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. *Journal of Clinical Oncology*, **2016**, 34, 8503-8503	2.2	36
64	CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).. *Journal of Clinical Oncology*, **2016**, 34, 8558-8558	2.2	1
63	Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. *PLoS ONE*, **2016**, 11, e0156728	3.7	52
62	Roots and routes of resistance. *Science Translational Medicine*, **2016**, 8,	17.5	1
61	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. *Translational Lung Cancer Research*, **2016**, 5, 727-730	4.4	11
60	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. *Journal of Physical Education and Sports Management*, **2016**, 2, e001263	2.8	13
59	Expression of tropomyosin 2 gene isoforms in human breast cancer cell lines. *Oncology Reports*, **2016**, 35, 3143-50	3.5	11
58	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. *Lung Cancer*, **2016**, 101, 104-110	5.9	13
57	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. *Journal of Clinical Oncology*, **2016**, 34, 4171-4179	2.2	173
56	Refining the treatment of NSCLC according to histological and molecular subtypes. *Nature Reviews Clinical Oncology*, **2015**, 12, 511-26	19.4	189
55	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. *BMC Cancer*, **2015**, 15, 376	4.8	16
54	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. *Journal of Clinical Oncology*, **2015**, 33, 1000-7	2.2	177
53	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. *Oncology Letters*, **2015**, 10, 1155-1158	2.6	10
52	Multiorgan autoimmune manifestations associated with thymoma. *Journal of Thoracic Oncology*, **2015**, 10, e5-7	8.9	9
51	Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. *Frontiers in Oncology*, **2015**, 5, 113	5.3	64
50	Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM) **2015**, 3,		2
49	Reply to A. Stenzinger et al. *Journal of Clinical Oncology*, **2015**, 33, 2824	2.2	
48	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 177-86	21.7	160

47	Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).. *Journal of Clinical Oncology*, **2015**, 33, 7565-7565	2.2	4
46	Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. *Oncotarget*, **2015**, 6, 4496-504	3.3	31
45	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. *Oncotarget*, **2015**, 6, 11694-703	3.3	47
44	Distinctive clinical characteristics of malignant mesothelioma in young patients. *Oncotarget*, **2015**, 6, 16766-73	3.3	31
43	Small cell lung cancer: Why has it become an orphan disease?. *Journal of Clinical Oncology*, **2015**, 33, 7578-7578	2.2	0
42	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. *Cancer*, **2014**, 120, 3311-9	6.4	115
41	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 191-200	21.7	83
40	Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. *Journal of Thoracic Oncology*, **2014**, 9, 567-71	8.9	26
39	Mutations of epigenetic regulatory genes are common in thymic carcinomas. *Scientific Reports*, **2014**, 4, 7336	4.9	85
38	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. *Clinical Cancer Research*, **2014**, 20, 5927-36	12.9	125
37	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. *Clinical Cancer Research*, **2014**, 20, 5392-402	12.9	71
36	Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. *Journal of Thoracic Oncology*, **2014**, 9, 1609-17	8.9	46
35	Novel biologic therapies for thymic epithelial tumors. *Frontiers in Oncology*, **2014**, 4, 103	5.3	9
34	Phase II trial of sunitinib in patients with thymic epithelial tumors (TET).. *Journal of Clinical Oncology*, **2014**, 32, 7525-7525	2.2	8
33	New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. *American Journal of Pathology*, **2013**, 182, 1065-77	5.8	82
32	Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. *Science Translational Medicine*, **2013**, 5, 208ra147	17.5	169
31	Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. *Clinical Lung Cancer*, **2013**, 14, 452-6	4.9	16
30	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. *Annals of Oncology*, **2013**, 24, 577-85	10.3	52

29	Farletuzumab in lung cancer. *Lung Cancer*, **2013**, 80, 15-8	5.9	21
28	Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. *Frontiers in Oncology*, **2013**, 3, 261	5.3	57
27	18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. *Clinical Cancer Research*, **2013**, 19, 1487-93	12.9	22
26	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. *Annals of Oncology*, **2013**, 24, 2601-2606	10.3	101
25	Characterization and management of cardiac involvement of thymic epithelial tumors. *Journal of Thoracic Oncology*, **2013**, 8, 246-9	8.9	13
24	"Pseudocavitation" in thymic carcinoma during treatment with sunitinib. *Journal of Thoracic Oncology*, **2013**, 8, 511-2	8.9	1
23	Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.. *Journal of Clinical Oncology*, **2013**, 31, 7513-7513	2.2	4
22	Second malignancies after multiple myeloma: from 1960s to 2010s. *Blood*, **2012**, 119, 2731-7	2.2	87
21	Immunotherapies for non-small-cell lung cancer and mesothelioma. *Lancet Oncology, The*, **2012**, 13, e301-10	21.9	83
20	Tyrosine kinase inhibitors in lung cancer. *Hematology/Oncology Clinics of North America*, **2012**, 26, 589-605, viii	3.1	24
19	Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 3425-6; author reply 3426	2.2	18
18	Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement. *Journal of Thoracic Oncology*, **2012**, 7, e29-31	8.9	17
17	Mesotheliomas **2012**, 319-334		
16	Phase II study of cixutumumab (IMC-A12) in thymic malignancies.. *Journal of Clinical Oncology*, **2012**, 30, 7033-7033	2.2	4
15	A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies.. *Journal of Clinical Oncology*, **2012**, 30, 7103-7103	2.2	4
14	Absence of mutation at the 5Rupstream promoter region of the TPM4 gene from cardiac mutant axolotl (Ambystoma mexicanum). *Cardiovascular Toxicology*, **2011**, 11, 235-43	3.4	11
13	Myeloma and second primary cancers. *New England Journal of Medicine*, **2011**, 365, 2241-2	59.2	42
12	Adult purpura fulminans associated with non-steroidal anti-inflammatory drug use. *Journal of Postgraduate Medicine*, **2011**, 57, 145-6	0.8	5

11	Thumbprinting. *Internal Medicine Journal*, **2010**, 40, 666	1.6	
10	Short communication: no evidence of HTLV-3 and HTLV-4 infection in New York State subjects at risk for retroviral infection. *AIDS Research and Human Retroviruses*, **2010**, 26, 1229-31	1.6	11
9	LGL leukemia and HTLV. *AIDS Research and Human Retroviruses*, **2010**, 26, 33-40	1.6	16
8	Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscle. *Journal of Cellular Biochemistry*, **2010**, 110, 875-81	4.7	20
7	Isolated CNS relapse of CML after bone marrow transplantation. *Leukemia Research*, **2010**, 34, e113-4	2.7	11
6	Colonic necrosis due to oral kayexalate in a critically-ill patient. *American Journal of the Medical Sciences*, **2009**, 337, 305-6	2.2	19
5	Osteopetrosis. *Postgraduate Medical Journal*, **2009**, 85, 250	2	1
4	Expression of Nkx2.5 in wild type, cardiac mutant, and thyroxine-induced metamorphosed hearts of the Mexican axolotl. *Cardiovascular Toxicology*, **2009**, 9, 13-20	3.4	11
3	Methyldopa-induced autoimmune haemolytic anaemia revisited. *New Zealand Medical Journal*, **2009**, 122, 53-6	0.8	7
2	Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult. *Cmaj*, **2008**, 179, 338-40	3.5	29
1	Neuroendocrine negative SCLC is mostly RB1 WT and may be sensitive to CDK4/6 inhibition		4